



October 9, 2019

Regd. Office: "Zydus Corporate Park", Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad - 382 481.

Code: 532 321

Listing Department BSE LIMITED P J Towers, Dalal Street, Fort, Mumbai-400 001

Listing Department

Code: CADILAHC NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai-400 051

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated October 9, 2019 titled "Zydus receives final approval from the USFDA for Colesevelam Hydrochloride Tablets."

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

AHMEDABAD

Thanking you,

Yours faithfully,

For, CADILA HEALTHCARE LIMITED

DHAVAL N. SONI COMPANY SECRETARY

Ders our

Encl.: As above

Regd. Office: 'Zydus Tower', Satollite Cross Reads, Ahmedabad 380 015, India. Phone: +91-79-2686 8100 (20 lines) www.zyduscadila.com CIN: L24230GJ1995PLC025878



Press Release

Press Release

Zydus receives final approval from the USFDA for Colesevelam Hydrochloride Tablets

Ahmedabad, 9 October, 2019

Zydus Cadila has received the final approval from the USFDA to market Colesevelam Hydrochloride Tablets, (US RLD - Welchol), 625 mg. This medication is used along with a proper diet and exercise, to lower cholesterol in people with high levels of cholesterol in the blood. Lowering cholesterol decreases the risk of heart disease and helps prevent strokes and heart attacks. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

The group now has 273 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 24,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

Phone: +91-79-2686 8100 (20 Lines) Fax: +91-79-2686 2365 www.zyduscadila.com

CIN: L24230GJ1995PLC025878